摘要
目的探讨孟鲁司特钠联合布地奈德治疗咳嗽变异性哮喘患儿的临床效果。方法选取2015年3月至2016年7月辽宁省营口市中医院收治的80例咳嗽变异性哮喘患儿作为研究对象,按随机数字表法将其分为对照组40例(布地奈德治疗)和研究组40例(孟鲁司特钠+布地奈德治疗),比较两组患儿临床疗效、症状改善时间及治疗时间、肺功能。结果研究组患儿治疗的总有效率为92.5%,明显高于对照组的77.5%,差异有统计学意义(P<0.05);研究组患儿咳嗽缓解和消失时间、总治疗时间均明显短于对照组,差异均有统计学意义(均P<0.05);治疗后,研究组患儿的第一秒钟用力呼气量与用力肺活量的百分比(FEV1/FVC)、呼气峰流速(PEF)、FEV1均明显高于对照组,差异均有统计学意义(均P<0.05)。结论临床治疗小儿咳嗽变异性哮喘疾病可考虑将孟鲁斯特和布地奈德联合使用,疗效突出,安全可靠,可有效改善肺功能。
Objective To investigate the clinical efficacy of Montelukast Combined with budesonide in the treatment of children with cough variant asthma.Methods From March 2015 to July 2016 in Yingkou Hospital of Traditional Chinese Medicine of Liaoning province from 80 cases of cough variant asthma in children as the research object,randomly divided into control group,40 cases and 40 cases（budesonide） study group（montelukast plus budesonide treatment）,compared two groups of children with clinical symptoms and therapeutic effects of time and the treatment time,lung function.Results The treatment group with the total effective rate was 92.5%,significantly higher than the control group 77.5%,the difference was statistically significant（P 〈 0.05）;the study group,the disappearance time of cough relief and total treatment time were significantly shorter than the control group,the differences were statistically significant（P〈0.05）;after treatment,the percentage of the first forced expiratory volume and FVC in the study group,the peak expiratory flow rate and FEV1 were significantly higher than the control group,the differences were statistically significant（P〈0.05）.Conclusion The clinical treatment of children with cough variant asthma disease can be considered to be the combined use of montelukast and budesonide prominent curative effect,safe and reliable,can effectively improve the lung function.
出处
《中国药物经济学》
2017年第7期103-104,114,共3页
China Journal of Pharmaceutical Economics
